Matthias Gijsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7840614/publications.pdf

Version: 2024-02-01

1162367 1125271 21 222 8 13 citations h-index g-index papers 23 23 23 228 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pharmacokinetics of 2 oral paracetamol formulations in hospitalized octogenarians. British Journal of Clinical Pharmacology, 2022, 88, 1020-1030.	1.1	5
2	Prospective assessment of breakthrough infections and neurotoxicity and their association with cefepime trough concentrations in patients with febrile neutropenia. International Journal of Antimicrobial Agents, 2022, 59, 106472.	1.1	7
3	Meropenem Target Attainment and Population Pharmacokinetics in Critically III Septic Patients with Preserved or Increased Renal Function. Infection and Drug Resistance, 2022, Volume 15, 53-62.	1.1	12
4	The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis. Intensive Care Medicine, 2022, 48, 768-769.	3.9	2
5	Editorial for the Special Issue: "Therapeutic Drug Monitoring of Antimicrobials― Antibiotics, 2022, 11, 815.	1.5	O
6	Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2022, 77, 2479-2488.	1.3	6
7	Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults. Pharmaceutics, 2022, 14, 1459.	2.0	1
8	Meropenem Stability in Human Plasma at \hat{a}^2 20 \hat{A}^2 C: Detailed Assessment of Degradation. Antibiotics, 2021, 10, 449.	1.5	8
9	Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study. Antibiotics, 2021, 10, 557.	1.5	9
10	Letter to the Editor regarding: Ceftriaxone exposure in patients undergoing extracorporeal membrane oxygenation. International Journal of Antimicrobial Agents, 2021, 57, 106326.	1.1	4
11	Meropenem Pharmacokinetics and Target Attainment in Critically III Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis. Microorganisms, 2021, 9, 1310.	1.6	14
12	Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. Antibiotics, 2021, 10, 1112.	1.5	5
13	Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine. Antibiotics, 2021, 10, 1182.	1.5	12
14	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2021, 76, 1234-1241.	1.3	14
15	Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients. Microorganisms, 2021, 9, 2068.	1.6	8
16	Cefepime therapeutic drug monitoring: Evaluation of agreement between peripheral and central venous blood sampling. Clinica Chimica Acta, 2020, 510, 450-454.	0.5	1
17	Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?. Frontiers in Pharmacology, 2020, $11,620$.	1.6	62
18	Can augmented renal clearance be detected using estimators of glomerular filtration rate?. Critical Care, 2020, 24, 359.	2.5	17

#	Article	IF	CITATIONS
19	Quantitative determination of colistin A/B and colistin methanesulfonate in biological samples using hydrophilic interaction chromatography tandem mass spectrometry. Drug Testing and Analysis, 2020, 12, 1183-1195.	1.6	13
20	Development and External Validation of an Online Clinical Prediction Model for Augmented Renal Clearance in Adult Mixed Critically Ill Patients: The Augmented Renal Clearance Predictor. Critical Care Medicine, 2020, 48, e1260-e1268.	0.4	14
21	Reliability of serum creatinineâ€based formulae estimating renal function in nonâ€critically ill surgery patients: Focus on augmented renal clearance. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 695-706.	0.7	8